Compare CLNN & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNN | IHD |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 112.6M |
| IPO Year | N/A | N/A |
| Metric | CLNN | IHD |
|---|---|---|
| Price | $3.98 | $6.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $32.67 | N/A |
| AVG Volume (30 Days) | ★ 124.8K | 27.7K |
| Earning Date | 03-23-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.32% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $214,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $82.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.28 | $4.49 |
| 52 Week High | $13.50 | $5.47 |
| Indicator | CLNN | IHD |
|---|---|---|
| Relative Strength Index (RSI) | 31.85 | 61.63 |
| Support Level | $3.88 | $6.73 |
| Resistance Level | $4.50 | $7.09 |
| Average True Range (ATR) | 0.42 | 0.11 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 5.16 | 40.00 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.